News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Sarah Rutherford, MD, Weill Cornell Medical College

Articles by Sarah Rutherford, MD, Weill Cornell Medical College

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in CLL

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

Latest Updated Articles

$ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas$
ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas
Published: January 22nd 2021 | Updated:
ASH 2020 Updates in CLL
Published: January 22nd 2021 | Updated:
ASH 2020 Updates in Non-CLL B-Cell Lymphomas
Published: January 22nd 2021 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL